<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-9190</journal-id>
<journal-title><![CDATA[Revista alergia México]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. alerg. Méx.]]></abbrev-journal-title>
<issn>2448-9190</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Inmunología Clínica y Alergia A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-91902025000400296</article-id>
<article-id pub-id-type="doi">10.29262/ram.v72i4.1508</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores de mal pronóstico en pacientes con artritis reumatoide]]></article-title>
<article-title xml:lang="en"><![CDATA[Poor prognostic factors in rheumatoid arthritis patients]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Morales]]></surname>
<given-names><![CDATA[María del Rocío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garcia-Vences]]></surname>
<given-names><![CDATA[Edna Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-López]]></surname>
<given-names><![CDATA[César Leonardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castellanos-Guerrero]]></surname>
<given-names><![CDATA[Ana Karen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cristóbal-Jiménez]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas-Guzmán]]></surname>
<given-names><![CDATA[Itzel Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Anáhuac México Norte Centro de Investigación en Ciencias de la Salud ]]></institution>
<addr-line><![CDATA[SSA Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Anáhuac México Norte Centro de Investigación en Ciencias de la Salud Secretaria de la Defensa Nacional, Escuela Militar de Graduados en Sanidad]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,SSA Puebla Servicio de Reumatología ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,SSA Puebla Servicio de Inmunología Clínica y Alergia ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>72</volume>
<numero>4</numero>
<fpage>296</fpage>
<lpage>304</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-91902025000400296&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-91902025000400296&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-91902025000400296&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Determinar los factores asociados con mal pronóstico de pacientes con artritis reumatoide de un hospital de tercer nivel de atención de Puebla.  Métodos: Estudio observacional, analítico, longitudinal, efectuado en una cohorte de pacientes con artritis reumatoide. Se siguieron durante un año, y se evaluaron como factores de mal pronóstico: sexo, comorbilidades, tabaquismo, DAS 28 (actividad de la enfermedad), VSG (velocidad de sedimentación globular), PCR (proteína C reactiva), ACCP (anticuerpo anti-péptido citrulinado), FR (factor reumatoide) y erosiones óseas. Para el análisis de los factores de mal pronóstico se realizó un análisis de riesgos proporcionales de Cox.  Resultados: Se incluyeron 260 pacientes; se registraron 26 fallas y 234 censuras. El género predominante fueron las mujeres, y la edad media se reportó de 47 ± 11.7 años. Los factores de mal pronóstico fueron: ACCP, inicio de FARME (fármacos antirreumáticos modificares de la enfermedad) tardío y tabaquismo. El ACCP positivo reportó 5.8 mayor riesgo de escalar tratamiento, FARME tardío 4.6 veces y los que fumaban 7.7 veces el riesgo.  Conclusiones: Definir los factores de mal pronóstico sigue siendo un gran reto para los investigadores; sin embargo, resulta ser imperioso identificarlos para predecir la respuesta al tratamiento y con ello limitar el daño funcional y de vida de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To determine the factors associated with a poor prognosis in patients with RA at a 3rd level hospital.  Methods: Observational, analytical, longitudinal study of a cohort of patients with RA. The study continued for one year. The following were assessed as PPFs: sex, comorbidities, smoking, DAS 28 (disease activity), ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), ACCP (anti-citrullinated peptide antibody), RF (rheumatoid factor), and bone erosions. To statistical analysis: A Cox proportional hazards analysis was performed to analyze PPFs.  Results: A total of 260 patients were included, 26 failures and 234 censored, predominantly female sex, mean age 47 ± 11.7 years, the PPFs were: ACCP, late start of DMARD, and smoking. ACCP positive have 5.8 times the risk of escalating treatment, late DMARD have 4.6 times and those who smoked 7.7 times the risk.  Conclusions: Defining the PPFs remains a great challenge for researchers, however, it is imperative to identify them to predict the response to treatment and thus limit the functional and life damage of patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Pronóstico]]></kwd>
<kwd lng="es"><![CDATA[Artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[Velocidad de sedimentación globular]]></kwd>
<kwd lng="es"><![CDATA[Proteína C reactiva]]></kwd>
<kwd lng="es"><![CDATA[Anticuerpo anti-péptido citrulinado]]></kwd>
<kwd lng="es"><![CDATA[Factor reumatoide]]></kwd>
<kwd lng="es"><![CDATA[Tabaquismo]]></kwd>
<kwd lng="en"><![CDATA[Prognosis]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[Erythrocyte sedimentation rate]]></kwd>
<kwd lng="en"><![CDATA[C-reactive protein]]></kwd>
<kwd lng="en"><![CDATA[Anti-citrullinated peptide antibody]]></kwd>
<kwd lng="en"><![CDATA[Rheumatoid factor]]></kwd>
<kwd lng="en"><![CDATA[Smoking]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deane]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Holers]]></surname>
<given-names><![CDATA[VM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Natural History of Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2019</year>
<volume>41</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1256-69</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gui]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The universal presence of poor prognostic factors based on EULAR recommendations: A real-world study in 1164 Chinese RA patients]]></article-title>
<source><![CDATA[Joint Bone Spine]]></source>
<year>2023</year>
<volume>90</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>105633</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romão]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
<name>
<surname><![CDATA[Fonseca]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Etiology and Risk Factors for Rheumatoid Arthritis: A State-of-the-Art Review]]></article-title>
<source><![CDATA[Front Med (Lausanne)]]></source>
<year>2021</year>
<volume>8</volume>
<page-range>689698</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alemao]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Litman]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2018</year>
<volume>45</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1353-60</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fraenkel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bathon]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Arthritis Care Res (Hoboken)]]></source>
<year>2021</year>
<volume>73</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>924-39</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[RBM]]></given-names>
</name>
<name>
<surname><![CDATA[Bergstra]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [published correction appears in Ann Rheum Dis 2023; 82 (3): e76. doi: 10.1136/ard-2022-223356corr1.]]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2023</year>
<volume>82</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-18</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Favalli]]></surname>
<given-names><![CDATA[EG]]></given-names>
</name>
<name>
<surname><![CDATA[Biggioggero]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Crotti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Becciolini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Raimondo]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Meroni]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex and Management of Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Clin Rev Allergy Immunol]]></source>
<year>2019</year>
<volume>56</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-45</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sokka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Toloza]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Cutolo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2009</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>R7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almoallim]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Al Saleh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Badsha]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Review of the Prevalence and Unmet Needs in the Management of Rheumatoid Arthritis in Africa and the Middle East]]></article-title>
<source><![CDATA[Rheumatol Ther]]></source>
<year>2021</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baganz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Richter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2019</year>
<volume>48</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>976-82</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ajeganova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huizinga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations]]></article-title>
<source><![CDATA[Ther Adv Musculoskelet Dis]]></source>
<year>2017</year>
<volume>9</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>249-62</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vittecoq]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Brevet]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gerard]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lequerre]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis]]></article-title>
<source><![CDATA[RMD Open]]></source>
<year>2024</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>e004472</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13.</label><nlm-citation citation-type="book">
<collab>Gobierno de México</collab>
<source><![CDATA[Diagnóstico y tratamiento de artritis reumatoide del adulto]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Ciudad de México ]]></publisher-loc>
<publisher-name><![CDATA[Gov mex]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weinstein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[McEVILLY]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dervieux]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2019</year>
<volume>46</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>657-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Conigliaro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Triggianese]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chimenti]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors]]></article-title>
<source><![CDATA[Isr Med Assoc J]]></source>
<year>2017</year>
<volume>19</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>467-72</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bird]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oakden-Rayner]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic modeling in early rheumatoid arthritis: reconsidering the predictive role of disease activity scores]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2024</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1503-12</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zink]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2017</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saevarsdottir]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wallin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Seddighzadeh]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2011</year>
<volume>70</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>469-75</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niewold]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Paget]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis]]></article-title>
<source><![CDATA[QJM]]></source>
<year>2007</year>
<volume>100</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>193-201</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harrold]]></surname>
<given-names><![CDATA[LR]]></given-names>
</name>
<name>
<surname><![CDATA[Bryson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lehman]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA]]></article-title>
<source><![CDATA[Rheumatol Ther]]></source>
<year>2021</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>937-53</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frazzei]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Musters]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Vries]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Tas]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevention of rheumatoid arthritis: A systematic literature review of preventive strategies in at-risk individuals]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2023</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>103217</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Javaid]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmud]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
<name>
<surname><![CDATA[Rasheed]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Javaid]]></surname>
<given-names><![CDATA[AUR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors Leading to Diagnostic and Therapeutic Delay of Rheumatoid Arthritis and Their Impact on Disease Outcome]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2023</year>
<volume>15</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>e34481</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maska]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Sayles]]></surname>
<given-names><![CDATA[HR]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Dell]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Care Res (Hoboken)]]></source>
<year>2012</year>
<volume>64</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1804-10</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>1.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gui]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The universal presence of poor prognostic factors based on EULAR recommendations: A real-world study in 1164 Chinese RA patients]]></article-title>
<source><![CDATA[Joint Bone Spine]]></source>
<year>2023</year>
<volume>90</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>105633</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>2.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alemao]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Litman]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2018</year>
<volume>45</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1353-60</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>3.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fraenkel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bathon]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[England]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis]]></article-title>
<source><![CDATA[Arthritis Care Res (Hoboken) 2021]]></source>
<year></year>
<volume>73</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>924-39</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>4.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smolen]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Landewé]]></surname>
<given-names><![CDATA[RBM]]></given-names>
</name>
<name>
<surname><![CDATA[Bergstra]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update [published correction appears in Ann Rheum Dis 2023; 82 (3): e76. doi: 10.1136/ard-2022-223356corr1.]]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2023</year>
<volume>82</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-18</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>5.</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baganz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Richter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Albrecht]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2019</year>
<volume>48</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>976-82</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
